Urica Therapeutics Inc.
A open label multi-center 3-period multidose, PK/PD and drug-drug interaction (DDI) study to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of 7 days of treatment with two doses of dotinurad monotherapy, and to evaluate the effect of dotinurad, as monotherapy and in combination with allopurinol, versus allopurinol monotherapy, on the PK of each, and to assess the additive PD effects on serum uric acid and urinary urate excretion in U.S. patients with gout and hyperuricemia
Gout
Hyperuricemia
dontinurad
dotinurad + allopurinol
allopurinol
PHASE1
PHASE2
Study Type : | INTERVENTIONAL |
Estimated Enrollment : | 20 participants |
Masking : | NONE |
Primary Purpose : | TREATMENT |
Official Title : | A Phase 1B Open Label Evaluation of the PK and PD of Dotinurad and Drug-Drug Interaction of Dotinurad and Allopurinol in U.S. Patients With Gout and Hyperuricemia |
Actual Study Start Date : | 2023-10 |
Estimated Primary Completion Date : | 2023-11 |
Estimated Study Completion Date : | 2023-11 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 18 Years to 75 Years |
Sexes Eligible for Study: | ALL |
Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
Clinical Research of West Florida
Clearwater, Florida, United States, 33765
RECRUITING
Panax Clinical Research
Miami Lakes, Florida, United States, 33014
RECRUITING
Southwest Rheumatology Research
Mesquite, Texas, United States, 75150
RECRUITING
Endeavor Clinical Trials
Saint Anthony, Texas, United States, 78240